| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Cynthia McLaughlin
Omar Beirat
Rosalio Madrigal
Cynthia McLaughlin
Jenna Brashear
| Share Statistics | ARCT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $461.2 | $282.5 | 36% |
|
| Shares Out (Mil) | 28.4 | 54.1 | 36% |
|
| Institutional Ownership | 91.0% | 92.9% | 59% |
|
| Float (Mil) | 26.2 | 41.5 | 33% |
|
| Beta | 2.27 | 0.94 | 95% |
|
| Avg Daily Volume (000s) | 2,302 | 469 | 85% |
|
| Price Change (52-week) |
(4.6%) | 59.1% | 43% |
|
| Growth | ARCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 53.9% | 14.1% | 96% |
|
| Net Income (5yr) | 1.8% | (10.1%) | 42% |
|
| EPS (5yr) | 7.5% | 15.9% | 43 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.2%) | (15.6%) | 45% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 9 | 10 | |
| Current EPS | ($0.670) | ($3.289) | ($3.718) | |
| Month Ago EPS | ($0.878) | ($3.858) | ($4.024) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.875) | ($3.867) | ($3.992) | |
| Year/Year Chg | (20.0%) | 36.9% | 46.5% | |
| Financials | ARCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $29 | $37 | 16% |
|
| Net Income (TTM) (Mil) | ($93) | ($43) | 12% |
|
| EPS (TTM) | ($3.327) | ($1.500) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($73) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($60) | $2 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $19 | $4 | 32% |
|
| Enterprise Value (Q1) (Mil) | $42 | $195 | 15% |
|
| Valuation | ARCT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.69 | 2.78 | 61% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ARCT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (195.5%) | 66.9% | 1% |
|
| Net Margin | (317.6%) | (74.2%) | 3% |
|
| ROA | (35.0%) | (47.6%) | 15% |
|
| ROE | (46.3%) | (55.0%) | 16% |
|
| Liabilities to Assets | 23.4% | 29.6% | 16% |
|
| F-Score | 1 | 3 | 1% |
|
Arcturus Therapeutics Holdings Inc. did not pass any screens on 9/1/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
